Clinical trials: Hypertension, Renal
Intraabdominal Hypertension, Abdominal Compartment Syndrome
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients.
- Conditions
- Intraabdominal Hypertension, Abdominal Compartment Syndrome, Acute Kidney Injury, Cardiovascular Surgery
- Trial name
- NCT04669548
- Testing
- Accuryn Monitoring System
- Where
- 9 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Potrero Medical
CHF, Renal Disease
Validation of a Sensor for Non-Invasive Measurements
Subjects will be measured with both a sensor and a reference device
- Conditions
- CHF, Renal Disease, Hypertension
- Trial name
- NCT03463148
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Baxter Healthcare Corporation
Pediatric Hypertension With or Without CKD
Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
To assess efficacy, safety and tolerability of valsartan when comparing two doses of valsartan in reducing and controlling blood pressure in children with hypertension with or without CKD.
- Trial name
- NCT01617681
- Testing
- VAL489
- Where
- 27 sites in Belgium, Brazil and 7 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Uncontrolled Hypertension
Renal Pelvic Denervation Pilot Trial
The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose.
- Trial name
- NCT07005050
- Testing
- RPD, Active hypertension medical therapy
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Verve Medical, Inc
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Hypertension, Early Diabetic Nephropathy
Antialbuminuric Effects of Valsartan and Lisinopril
Title: Antialbuminuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), open label, parallel group, 20 weeks follow-up.
- Trial name
- NCT00171600
- Testing
- VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- Novartis
Hypertension, Renal Insufficiency, Chronic
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
The purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney…
- Trial name
- INSPIRE-CKD (NCT04162366)
- Testing
- Aprocitentan 25 mg
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients
Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)
Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan
- Conditions
- Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients, Routine Therapy Before and After the Diagnosis of CKD
- Trial name
- D1843R00359 (NCT06744335)
- Where
- 28 sites in Kazakhstan
- Volunteers
- 1,283 people
- Sponsor
- AstraZeneca
Hypertension, Diabetes Mellitus, Type 2
INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria
A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy…
- Trial name
- NCT01398423
- Testing
- Active Control, INV-144
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- InVasc Therapeutics, Inc.
Hypertension, Type 2 Diabetes
Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive
The objective of the study is to evaluate the safety of multi-organ denervation using the Integrated Radio Frequency (iRF) Denervation System. and to understand any potential improvement in hypertension and glycemic control.
- Conditions
- Hypertension, Type 2 Diabetes, Metabolic Syndrome
- Trial name
- MODUS (NCT04917393)
- Testing
- iRF System Multi-organ Denervation, Control Procedure
- Where
- 2 sites in Georgia
- Volunteers
- 45 people
- Sponsor
- Metavention
Hypertension
TARGET BP I Clinical Trial
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group…
- Trial name
- TARGET BP I (NCT02910414)
- Testing
- Dehydrated alcohol
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Ablative Solutions, Inc.
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Multivessel Coronary Artery Disease, Hypertension Resistant to Conventional Therapy
Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE
EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for…
- Trial name
- EMBRACE (NCT07602790)
- Testing
- Renal denervation
- Volunteers
- 1,000 people
- Sponsor
- Ceric Sàrl
Chronic Kidney Disease, Hypertension
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly.
- Trial name
- NCT05491642
- Testing
- BAY3283142
- Where
- 4 sites in Bulgaria, Germany
- Volunteers
- 56 people
- Sponsor
- Bayer
Chronic Kidney Disease, Hypertension
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone.
- Conditions
- Chronic Kidney Disease, Hypertension, Hyperkalemia
- Trial name
- AMETHYST-DN (NCT01371747)
- Testing
- patiromer, losartan, spironolactone
- Where
- 43 sites in Croatia, Georgia and 3 more
- Volunteers
- 324 people
- Sponsor
- Relypsa, Inc.
Hypertension, Diabetes
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.
- Trial name
- BENEDICT (NCT00235014)
- Testing
- trandolapril, trandolapril/verapamil, verapamil
- Volunteers
- 1,204 people
- Sponsor
- Abbott
Uncontrolled Hypertension, Chronic Kidney Diseases
A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).
- Trial name
- NCT05432167
- Testing
- CIN-107
- Where
- 71 sites in United States
- Volunteers
- 195 people
- Sponsor
- AstraZeneca
Hypertension, Heart Failure
OneShot Renal Denervation Registry
This is a multi-center, prospective registry designed to monitor the outcomes of renal denervation with the OneShot Device in a real-world patient population.
- Conditions
- Hypertension, Heart Failure, Diabetes Mellitus, Sleep Apnea
- Trial name
- NCT01844037
- Testing
- OneShot Ablation System
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Medtronic Endovascular
Hypertension
Renal Denervation in Patients With Refractory Hypertension
The purpose of this study is to investigate the clinical utility of renal denervation for the treatment of refractory hypertension.
- Trial name
- NCT00753285
- Testing
- Renal Denervation
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Medtronic Vascular
Hypertension, Hyperhomocysteinemia
CSPPT- Chronic Kidney Diseases Study
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing renal function decline among the patients with primary hypertension when compared to enalapril maleate.
- Trial name
- CSPPT-CKD (NCT01871740)
- Testing
- Enalapril maleate and folic acid tablets, Enalapril maleate
- Where
- 2 sites in China
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd